Articles related to RETINA

The FDA approved Lytenava as the first ophthalmic bevacizumab formulation for wet AMD. The decision moves bevacizumab beyond repackaged intravenous use, with launch logistics still pending.

Ocular Therapeutix announced FDA alignment on a planned fourth-quarter 2026 NDA submission for Axpaxli in wet AMD, based on SOL-1 phase 3 efficacy data and interim safety results from the ongoing SOL-R trial.

AREDS2 remains the evidence-based standard for AMD supplementation, but expanding understanding of complement dysregulation, mitochondrial dysfunction, and macular carotenoid biology has prompted discussion about whether a next-generation formulation could address pathways the current one does not target.

Erucamide, a naturally occurring lipid molecule, declined as photoreceptors deteriorated in preclinical retinal degeneration models, and restoring it via nanoparticle delivery slowed aspects of tissue breakdown without reversing damage.

Vitreoretinal surgeons describe off-label fibrin glue application as a localized tamponade alternative for rhegmatogenous retinal detachment repair, hemorrhage control, and retinal edge stabilization in cases where gas or silicone oil poses prohibitive patient or logistical constraints.

OCT, B-scan ultrasound, and ultrasound biomicroscopy identified distinct structural signatures across hypotony sequelae including maculopathy, choroidal detachment, and cyclodialysis cleft in cases where slit-lamp examination and indirect ophthalmoscopy alone proved insufficient.